CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sagent Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sagent Pharmaceuticals Inc
1901 N Roselle Rd Ste 700
Phone: (847) 908-1604p:847 908-1604 SCHAUMBURG, IL  60195-3194  United States Fax: (302) 674-5266f:302 674-5266

This company was Merged or Acquired on 8/29/2016.
This company ceased filing statements with the SEC on 9/9/2016.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201612/31/2015YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Lead Independent Director Robert J.Flanagan 60 6/1/2015 5/1/2009
Chief Executive Officer, Director AllanOberman 58 9/1/2015 9/1/2015
Chief Financial Officer, Executive Vice President Jonathon M.Singer 52 1/1/2016 9/1/2011
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Kanghong Sagent (Chengdu) Pharmaceutical Co. Ltd.
Omega Laboratories Ltd.
Sagent (China) Pharmaceuticals Co. Ltd.
4 additional Business Names available in full report.

General Information
Number of Employees: 440 (As of 12/31/2015)
Outstanding Shares: 32,910,475 (As of 7/29/2016)
Shareholders: 8,123
Stock Exchange: NASD
Fax Number: (302) 674-5266


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023